Stefan Lohmer, PhD, is the President, Chief Executive Officer and Founder of Axxam. Since its inception in 2001, he has positioned Axxam as an innovator for the identification of bioactive small molecules by applying high throughput screening for membrane proteins like GPCRs, Transporters and Ion Channels.
Dr. Lohmer brings more than 25 years of experience in the field of small molecule drug discovery. Prior to founding Axxam, he held various positions with increasing seniority at Bayer Pharmaceuticals, culminating in the World Wide Head of Genomics.
Dr. Lohmer holds a PhD in Molecular Biology and Genetics from the Albertus Magnus University Koeln, Germany. He is an inventor on 18 patents and has authored 20 peer-reviewed publications. Dr. Lohmer has also an observer seat on the Board in Acousia Therapeutics, a company dedicated for generating treatment opportunities for hearing loss.